FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2979881407> ?p ?o ?g. }

• W2979881407 endingPage "1063" @default.
• W2979881407 startingPage "1063" @default.
• W2979881407 abstract "Abstract Introduction: Patients with RR-AML, particularly older adults, have dismal outcomes and limited therapy options. Given low response rates and high toxicity with salvage intensive chemotherapy, and frequent ineligibility for allogeneic stem cell transplantation (alloSCT), many patients are treated with HMAs. Robust data regarding use of HMAs in AML predominates in the frontline setting, while their use in RR-AML has limited supportive data. Here wesought to analyze theoutcomes and their predictors in patients with RR-AML treated with HMAs. Methods:We collected data, spanning a period from 2006 to 2016, from 7 centers in the United States and 4 centers in Europe regarding patients treated with HMAs for RR-AML. Responses were defined by International Working Group criteria. Kaplan-Meier methods estimated overall survival (OS) from initiation of HMAs to death or end of follow-up. Multivariable logistic regression models estimated odds for response, and multivariable Cox Proportional Hazard (CPH) models estimated hazards ratios (HR) for OS. Covariates considered included HMA received, age at diagnosis (in years), AML classification at diagnosis (AML with myelodysplasia-related changes [AML-MRC], therapy-related [t]-AML), disease status (relapsed vs. refractory), number of therapy lines prior to HMA (1 vs. 2 vs. >=3), duration of first complete remission (CR1), white blood cell count, peripheral blood blast percentage, bone marrow (BM) cellularity (<=20% vs. > 20%), BM blast percentage (<=20% vs. >20%), cytogenetic risk group, and the presence of complex or chromosome 7 abnormalities. Results: Of 514 patients, 217 patients (42.2%) had refractory and 297 (58%) had relapsed AML. By end of study, 415 patients (88.5%) had died. Median follow-up for living patients was 11.6 months.Median age at diagnosis was 64 years (range [R], 16-92). AML-MRC was diagnosed in 29.0% while 8.2% had t-AML. Median number of prior therapies was 2 (R, 1-7), with 48.3% receiving 1 prior line, 30.2% receiving 2 prior lines, and 21.5% receiving >=3 prior lines. Prior alloSCT was performed in 21.2%. Only 1.9% had good risk (core binding factor) karyotype, while 56.2% had intermediate risk karyotype, and 41.9% had poor risk karyotype. Azacitidine was used in 45.8% and decitabine in 54.2%; median number of azacitidine cycles was 4 (Interquartile range [IQR], 2-6) compared to 2 for decitabine (IQR, 1-4, p <0.001). Best response to HMAs was CR in 11.7% (95%CI, 9%-14%), CRi in 6.4% (95%CI, 4.3%-8.8%), hematologic improvement (HI) in 8% (95%CI, 5.7%-10.5%), stable disease (SD) in 9.8% (95%CI, 7.2%-12.5%), while 64.1% (95%CI, 57.7%-66.2%) had progressive disease (PD). Median OS from HMA initiation for all patients was 6.9 months (IQR, 3.0-13.3). There was a significant difference in OS based on best response achieved [Figure 1]. Unadjusted OS showed an insignificant trend for worsening with increasing number of prior lines of therapy [Figure 2A]. In unadjusted analyses, there was no difference in OS based on HMA received in all patients [Figure 2B] or the subset who received only 1 prior line of therapy (median OS: Azacitidine vs. decitabine 8.4 vs 7.3 months, p=0.88). Following HMA therapy, the median number of subsequent therapies was 0 (R, 0-6), and only 12.8% underwent alloSCT. In multivariate CPH models, HMA used was not significantly associated with OS (HR=0.80, 95%CI, 0.42-1.51, p=0.49), while increasing age, and presence of complex cytogenetics and chromosome 7 abnormalities were significantly associated with risk of death [Table 1]. In multivariable logistic regression models, HMA used was not associated with achieving CR+CRi (Odds ratio=0.56, p=0.32). Conclusions: In this largest reported cohort of patients with RR-AML treated with HMAs, we found that HMAs are often used as alast line of therapy, with a minority of patients receiving subsequent treatment. Nonetheless, the minority of patients who achieve CR (11.7%) with HMA therapy had a median OS of 25.6 months. Therefore, use of HMAs for management of RR-AML is a reasonable intervention in the absence of clinical trial options. There appears to be no difference in OS or probability of achieving CR+CRi based on HMA used. Ongoing analyses in this dataset include further evaluations of predictors, including genetic mutations, and the development of prediction tools for clinical outcomes with HMA therapy. Figure 1. Figure 1. Disclosures Podoltsev: Ariad: Consultancy, Honoraria; Incyte: Consultancy, Honoraria. Ritchie:Novartis: Honoraria; Incyte: Speakers Bureau; Arian: Speakers Bureau; Pfizer: Honoraria; Celgene: Speakers Bureau. Sekeres:Millenium/Takeda: Membership on an entity's Board of Directors or advisory committees; Celgene: Membership on an entity's Board of Directors or advisory committees. Komrokji:Celgene: Membership on an entity's Board of Directors or advisory committees, Research Funding; Novartis: Consultancy, Speakers Bureau. Al-Kali:Onconova Therapeutics, Inc.: Research Funding; Celgene: Research Funding. Santini:Celgene: Consultancy, Honoraria, Research Funding; Janssen: Consultancy, Honoraria; Novartis: Consultancy, Honoraria; Onconova: Consultancy; Amgen: Consultancy; Astex: Consultancy. Roboz:Cellectis: Research Funding; Agios, Amgen, Amphivena, Astex, AstraZeneca, Boehringer Ingelheim, Celator, Celgene, Genoptix, Janssen, Juno, MEI Pharma, MedImmune, Novartis, Onconova, Pfizer, Roche/Genentech, Sunesis, Teva: Consultancy. Fenaux:Celgene, Janssen,Novartis, Astex, Teva: Honoraria, Research Funding. Prebet:celgene: Consultancy, Honoraria; Novartis: Consultancy, Honoraria. Gore:celgene: Consultancy, Honoraria. Zeidan:Ariad: Consultancy, Honoraria; Pfizer: Consultancy, Honoraria; Incyte: Consultancy, Honoraria; Celgene: Consultancy, Honoraria." @default.
• W2979881407 created "2019-10-18" @default.
• W2979881407 creator A5000296770 @default.
• W2979881407 creator A5004876764 @default.
• W2979881407 creator A5005172825 @default.
• W2979881407 creator A5008422091 @default.
• W2979881407 creator A5009387581 @default.
• W2979881407 creator A5010057352 @default.
• W2979881407 creator A5010075752 @default.
• W2979881407 creator A5012863731 @default.
• W2979881407 creator A5013969487 @default.
• W2979881407 creator A5014838075 @default.
• W2979881407 creator A5015755664 @default.
• W2979881407 creator A5035222674 @default.
• W2979881407 creator A5042026379 @default.
• W2979881407 creator A5051793137 @default.
• W2979881407 creator A5052920087 @default.
• W2979881407 creator A5053724616 @default.
• W2979881407 creator A5055740968 @default.
• W2979881407 creator A5057178417 @default.
• W2979881407 creator A5058151551 @default.
• W2979881407 creator A5067521829 @default.
• W2979881407 creator A5071827540 @default.
• W2979881407 creator A5078887304 @default.
• W2979881407 creator A5080661528 @default.
• W2979881407 creator A5085360755 @default.
• W2979881407 creator A5090619252 @default.
• W2979881407 creator A5091318797 @default.
• W2979881407 date "2016-12-02" @default.
• W2979881407 modified "2023-10-01" @default.
• W2979881407 title "The Use of Hypomethylating Agents (HMAs) in Patients with Relapsed and Refractory Acute Myeloid Leukemia (RR-AML): Clinical Outcomes and Their Predictors in a Large International Patient Cohort" @default.
• W2979881407 doi "https://doi.org/10.1182/blood.v128.22.1063.1063" @default.
• W2979881407 hasPublicationYear "2016" @default.
• W2979881407 type Work @default.
• W2979881407 sameAs 2979881407 @default.
• W2979881407 citedByCount "3" @default.
• W2979881407 countsByYear W29798814072017 @default.
• W2979881407 countsByYear W29798814072019 @default.
• W2979881407 crossrefType "journal-article" @default.
• W2979881407 hasAuthorship W2979881407A5000296770 @default.
• W2979881407 hasAuthorship W2979881407A5004876764 @default.
• W2979881407 hasAuthorship W2979881407A5005172825 @default.
• W2979881407 hasAuthorship W2979881407A5008422091 @default.
• W2979881407 hasAuthorship W2979881407A5009387581 @default.
• W2979881407 hasAuthorship W2979881407A5010057352 @default.
• W2979881407 hasAuthorship W2979881407A5010075752 @default.
• W2979881407 hasAuthorship W2979881407A5012863731 @default.
• W2979881407 hasAuthorship W2979881407A5013969487 @default.
• W2979881407 hasAuthorship W2979881407A5014838075 @default.
• W2979881407 hasAuthorship W2979881407A5015755664 @default.
• W2979881407 hasAuthorship W2979881407A5035222674 @default.
• W2979881407 hasAuthorship W2979881407A5042026379 @default.
• W2979881407 hasAuthorship W2979881407A5051793137 @default.
• W2979881407 hasAuthorship W2979881407A5052920087 @default.
• W2979881407 hasAuthorship W2979881407A5053724616 @default.
• W2979881407 hasAuthorship W2979881407A5055740968 @default.
• W2979881407 hasAuthorship W2979881407A5057178417 @default.
• W2979881407 hasAuthorship W2979881407A5058151551 @default.
• W2979881407 hasAuthorship W2979881407A5067521829 @default.
• W2979881407 hasAuthorship W2979881407A5071827540 @default.
• W2979881407 hasAuthorship W2979881407A5078887304 @default.
• W2979881407 hasAuthorship W2979881407A5080661528 @default.
• W2979881407 hasAuthorship W2979881407A5085360755 @default.
• W2979881407 hasAuthorship W2979881407A5090619252 @default.
• W2979881407 hasAuthorship W2979881407A5091318797 @default.
• W2979881407 hasConcept C126322002 @default.
• W2979881407 hasConcept C143998085 @default.
• W2979881407 hasConcept C207103383 @default.
• W2979881407 hasConcept C2778729363 @default.
• W2979881407 hasConcept C44249647 @default.
• W2979881407 hasConcept C50382708 @default.
• W2979881407 hasConcept C71924100 @default.
• W2979881407 hasConcept C72563966 @default.
• W2979881407 hasConceptScore W2979881407C126322002 @default.
• W2979881407 hasConceptScore W2979881407C143998085 @default.
• W2979881407 hasConceptScore W2979881407C207103383 @default.
• W2979881407 hasConceptScore W2979881407C2778729363 @default.
• W2979881407 hasConceptScore W2979881407C44249647 @default.
• W2979881407 hasConceptScore W2979881407C50382708 @default.
• W2979881407 hasConceptScore W2979881407C71924100 @default.
• W2979881407 hasConceptScore W2979881407C72563966 @default.
• W2979881407 hasIssue "22" @default.
• W2979881407 hasLocation W29798814071 @default.
• W2979881407 hasOpenAccess W2979881407 @default.
• W2979881407 hasPrimaryLocation W29798814071 @default.
• W2979881407 hasRelatedWork W2572837865 @default.
• W2979881407 hasRelatedWork W2760851598 @default.
• W2979881407 hasRelatedWork W2809909380 @default.
• W2979881407 hasRelatedWork W2970151791 @default.
• W2979881407 hasRelatedWork W2972456598 @default.
• W2979881407 hasRelatedWork W2980864243 @default.
• W2979881407 hasRelatedWork W3113787349 @default.
• W2979881407 hasRelatedWork W3129483513 @default.
• W2979881407 hasRelatedWork W4281560766 @default.
• W2979881407 hasRelatedWork W4283016565 @default.
• W2979881407 hasVolume "128" @default.
• W2979881407 isParatext "false" @default.
• W2979881407 isRetracted "false" @default.

• next